CTMX Q1 2018 Earnings — CytomX Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

CTMXCytomX Therapeutics, Inc.

$822M

Q1 2018 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$14M+21.7% YoY

Gross Profit

$14M100.0% margin

Operating Income

-$16M-110.2% margin

Net Income

-$15M-109.2% margin

EPS (Diluted)

$-0.40

QoQ Revenue Growth

-47.6%

Cash Flow

Operating Cash Flow

-$15M

Free Cash Flow

-$15M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$376M

Total Liabilities

$327M

Stockholders' Equity

$50M

Cash & Equivalents

$142M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$14M	$12M	+21.7%
Gross Profit	$14M	$12M	+21.7%
Operating Income	-$16M	-$9M	-81.4%
Net Income	-$15M	-$8M	-87.6%

Revenue Segments

E G F R Products

$44M91%

Amgen Other Products

$4M9%